Alaunos Therapeutics, Inc. Asset Impairment Charges
Alaunos Therapeutics, Inc. (TCRT) reported Asset Impairment Charges of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2025-03-31
- Alaunos Therapeutics, Inc. asset impairment charges for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. asset impairment charges for the quarter ending 2023-12-31 was $3.79M.
- Alaunos Therapeutics, Inc. asset impairment charges for the quarter ending 2022-12-31 was $0.00.
- Alaunos Therapeutics, Inc. asset impairment charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Alaunos Therapeutics, Inc. asset impairment charges for fiscal 2023 was $4.80M.
- Alaunos Therapeutics, Inc. asset impairment charges for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Alaunos Therapeutics, Inc. asset impairment charges for fiscal 2021 was $740.00K.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.80M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.01M 10-Q · filed 2024-11-14 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 10-K · filed 2024-04-01 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | ||
| 2021-12-31 | $740.00K 10-K · filed 2023-03-07 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |